<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521140</url>
  </required_header>
  <id_info>
    <org_study_id>AVC-002</org_study_id>
    <nct_id>NCT04521140</nct_id>
  </id_info>
  <brief_title>Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery</brief_title>
  <official_title>Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Prednisolone Acetate 1% Treating Pain, and inflamMation Following Corneal Transplant Surgery Compared to Topical Prednisolone Acetate 1%.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicole Fram M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Vision Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg insert&#xD;
      following corneal transplant surgery (PKP, DSEK, DMEK) as compared to topical prednisolone&#xD;
      acetate 1%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg insert,&#xD;
      when placed within the lower or upper eye lid canaliculus in conjunction with topical&#xD;
      prednisolone acetate 1% for the treatment of pain, and inflammation following corneal&#xD;
      transplant surgery (PKP, DSEK, DMEK) as compared to topical prednisolone acetate 1%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In patient who undergo corneal transplant (PKP,DSEK,DMEK), subjects will be randomized to 6 arms and be followed for a period of 3 months.&#xD;
First arm will Receive Dextenza with PKP, Second arm will receive Prednisolone Acetate 1% with PKP, Third arm will Receive Dextenza with DSEK, Forth arm will receive Prednisolone Acetate 1% with DSEK Fifth arm will Receive Dextenza with DMEK, Sixth arm will receive Prednisolone Acetate 1% with DMEK</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in pain score</measure>
    <time_frame>Assessed on Day 1,7 and 30</time_frame>
    <description>as measured with the visual analog scale (VAS); between 0 and 100; 0 meaning no pain and 100 meaning worst pain possible</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in inflammation (Cell and Flare) scores</measure>
    <time_frame>Assessed on Day 1,7 and 30</time_frame>
    <description>as measured by SUN (Standardization on Uveitis Nomenclature) grading scale: absence of cell to be defined as a grade of 0-0.5 and absence of flare to be defined as a grade of: 0-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in duration to corneal re-epithelization</measure>
    <time_frame>Assessed on Day 1 and 7</time_frame>
    <description>as measured by clinical observation of percentage (%); between 0 to 100%; 0 meaning complete re-epithalization and 100% meaning total corneal defect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in size of epithelial defect</measure>
    <time_frame>Assessed on Day 1 and 7</time_frame>
    <description>as measured by diameter (mm) of defect; 0 meaning no defect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on the practice/medical team of decreasing the drop burden</measure>
    <time_frame>Assessed on day 30</time_frame>
    <description>as measured by a questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in duration to clearing of corneal edema</measure>
    <time_frame>Assessed on Day 30, 60 and 90</time_frame>
    <description>as measured by clinical observation; between 0 to 3; 0 meaning clear cornea and 3+ meaning complete obscuration of anterior chamber and iris</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Corneal Edema</condition>
  <condition>Corneal Defect</condition>
  <condition>Corneal Transplant</condition>
  <condition>Penetrating KeratoPlasty</condition>
  <condition>Anterior Chamber Inflammation</condition>
  <condition>Ocular Pain</condition>
  <arm_group>
    <arm_group_label>PKP with Dextenza (study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing PKP will receive Dextenza insert with:&#xD;
topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.&#xD;
PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PKP without Dextenza (Controlled)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients undergoing PKP will receive:&#xD;
topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.&#xD;
PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSEK with Dextenza (study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing DSEK will receive Dextenza insert with:&#xD;
topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.&#xD;
PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSEK without Dextenza (Controlled)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients undergoing DSEK will receive:&#xD;
topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.&#xD;
PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMEK with Dextenza (study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive Dextenza insert with: topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.&#xD;
PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMEK without Dextenza (Controlled)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients undergoing DMEK will receive:&#xD;
topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.&#xD;
PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza 0.4Mg Ophthalmic Insert</intervention_name>
    <description>DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.</description>
    <arm_group_label>DMEK with Dextenza (study)</arm_group_label>
    <arm_group_label>DSEK with Dextenza (study)</arm_group_label>
    <arm_group_label>PKP with Dextenza (study)</arm_group_label>
    <other_name>Dexamethasone Ophthalmic Insert</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 1% Oph Susp</intervention_name>
    <description>Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection</description>
    <arm_group_label>DMEK with Dextenza (study)</arm_group_label>
    <arm_group_label>DMEK without Dextenza (Controlled)</arm_group_label>
    <arm_group_label>DSEK with Dextenza (study)</arm_group_label>
    <arm_group_label>DSEK without Dextenza (Controlled)</arm_group_label>
    <arm_group_label>PKP with Dextenza (study)</arm_group_label>
    <arm_group_label>PKP without Dextenza (Controlled)</arm_group_label>
    <other_name>Omnipred, Pred Forte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: A patient's study eye must meet the following criteria to be eligible&#xD;
        for inclusion in the study:&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Scheduled corneal transplant surgery: PKP, DSEK, DMEK&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study related procedures&#xD;
&#xD;
          -  Willing and able to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria: A patient who meets any of the following criteria will be excluded from&#xD;
        the study:&#xD;
&#xD;
          -  Patients under the age of 18.&#xD;
&#xD;
          -  Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)&#xD;
&#xD;
          -  Active infectious systemic disease&#xD;
&#xD;
          -  Active infectious ocular or extraocular disease&#xD;
&#xD;
          -  Presence of punctal plug in the study eye&#xD;
&#xD;
          -  Obstructed nasolacrimal duct in the study eye(s)&#xD;
&#xD;
          -  Hypersensitivity to dexamethasone or prednisolone eye drops&#xD;
&#xD;
          -  Patients being treated with immunomodulating agents in the study eye(s)&#xD;
&#xD;
          -  Patients being treated with immunosuppressants and/or oral steroids&#xD;
&#xD;
          -  Patients with severe disease that warrants critical attention, deemed unsafe for the&#xD;
             study by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Fram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Vision Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole R Fram, M.D.</last_name>
    <phone>310-229-1220</phone>
    <email>nicfram@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Orly Shiler</last_name>
    <phone>310-229-1220</phone>
    <email>orlyjr@inorbit.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Advanced Vision Care</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orly Shiler</last_name>
      <phone>310-229-1220</phone>
      <email>orlyjr@inorbit.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Anshu A, Price MO, Price FW Jr. Risk of corneal transplant rejection significantly reduced with Descemet's membrane endothelial keratoplasty. Ophthalmology. 2012 Mar;119(3):536-40. doi: 10.1016/j.ophtha.2011.09.019. Epub 2012 Jan 3.</citation>
    <PMID>22218143</PMID>
  </reference>
  <reference>
    <citation>Price MO, Scanameo A, Feng MT, Price FW Jr. Descemet's Membrane Endothelial Keratoplasty: Risk of Immunologic Rejection Episodes after Discontinuing Topical Corticosteroids. Ophthalmology. 2016 Jun;123(6):1232-6. doi: 10.1016/j.ophtha.2016.02.001. Epub 2016 Mar 13.</citation>
    <PMID>26983976</PMID>
  </reference>
  <reference>
    <citation>Tyson SL, Bafna S, Gira JP, Goldberg DF, Jones JJ, Jones MP, Kim JK, Martel JM, Nordlund ML, Piovanetti-Perez IK, Singh IP, Metzinger JL, Mulani D, Sane S, Talamo JH, Goldstein MH; Dextenza Study Group. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019 Feb;45(2):204-212. doi: 10.1016/j.jcrs.2018.09.023. Epub 2018 Oct 24. Erratum in: J Cataract Refract Surg. 2019 Jun;45(6):895.</citation>
    <PMID>30367938</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Advanced Vision Care</investigator_affiliation>
    <investigator_full_name>Nicole Fram M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Edema</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

